BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion. Revenue is projected to grow 123% this year and 79.63% next year, though earnings will dip 61.11% before rebounding 44.41%. Despite bullish analyst sentiment, BBIO’s 12.3% short interest and volatility warrant caution. Today’s Featured Stock Valued at $13.8 billion, BridgeBio Pharma (BBIO) discovers, develops and innovates ...